glp-1 receptor agonist and dpp-4 inhibitor combination contraindicated Frontiers | inhibitors for treating T2DM The effect of DPP-4 inhibitors,

The bottom line: Our findings suggest that GLP-1RA and SGLT2i (and especially SGLT2i with the lowest number needed to treat (NNT) for nearly all study outcomes) may be the preferred glucose-lowering agents for cardiovascular risk reduction in patients at moderate risk for CVD, building on and consistent with existing RCT evidence in the high-risk population. This report highlights potential preference for GLP-1 drugs as a first-line treatment for Type 2 diabetes related to its cardioprotective effect

Patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, a history of pancreatitis, or certain other conditions should discuss those specifics with a qualified provider before exploring GLP-1 treatment through any channel

Pathogenic variants whose gene products function upstream of the MC4R could be bypassed with agonists for the receptor

Clin Pharmacol Ther

doi: 10.2147/CEG.S184016